We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02288975
Recruitment Status : Completed
First Posted : November 13, 2014
Last Update Posted : March 27, 2018
Information provided by (Responsible Party):
Zsolt Molnár, MD, PhD, DEAA, Szeged University

Brief Summary:
The aim of the study is to investigate the effect of CytoSorb® treatment within the first 48 hours of septic shock on organ dysfunction, microcirculation and on the cytokine storm as monitored by leukocyte activation and inflammatory mediators.

Condition or disease Intervention/treatment
Sepsis Septic Shock Device: CytoSorb 300ml device (3804606CE01)

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock
Study Start Date : October 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Group/Cohort Intervention/treatment
Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
Device: CytoSorb 300ml device (3804606CE01)
Patients with septic shock will get routine ICU care.

Primary Outcome Measures :
  1. Cytokine response [ Time Frame: First 48 hours of septic shock ]
    Cytokine response: procalcitonin, C-reactive protein, interleukin-1, interleukin-1ra, interleukin-6, interleukin-8, interleukin-10, Tumor Necrosis Factor- α

  2. Organ dysfunctions [ Time Frame: First 48 hours of septic shock ]
    Organ dysfunctions: SOFA-scores, neurologic function (Glasgow coma scale), hemodynamic function (PiCCO parameters, ScvO2, lactate, dCO2), pulmonary function (gas exchange, pulmonary mechanics, Acute Respiratory Distress Syndrome classification (BERLIN)), renal function (KDIGO-, RIFLE-scores), gastrointestinal function (liver, GIT function, hematology (hemostasis, qualitative blood count)

Secondary Outcome Measures :
  1. Leukocyte function [ Time Frame: First 48 hours of septic shock ]
    Leukocyte function: heterogeneity of leukocyte cell population in the bloodstream, T-cell activation and apoptosis, leukocyte inflammatory markers expression

  2. Microcirculation [ Time Frame: First 48 hours of septic shock ]
    Microcirculation: orthogonal polarization spectroscopy (OPS), gastric tonometry

Other Outcome Measures:
  1. Length of intensive care unit stay, [ Time Frame: First 48 hours of septic shock ]
  2. Length of hospital stay [ Time Frame: First 48 hours of septic shock ]
  3. Mortality [ Time Frame: First 48 hours of septic shock ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
ICU patients with septic shock of medical origin

Inclusion Criteria:

  • Signs of hypoperfusion: serum lactate >2 mmol/L, low central venous oxygen saturation (ScvO2) (<70%) or high ScvO2 (>85%), metabolic acidosis, oligo-anuria, high venous-to-arterial CO2-gap (dCO2 >6 mm Hg)
  • Hemodynamic support with vasopressors
  • Procalcitonin level ≥ 3 ng/ml
  • Invasive hemodynamic monitoring
  • Written informed content

Exclusion Criteria:

  • Patients under 18 years
  • Pregnancy (bHCG test positivity)
  • Surgical intervention in context with the septic insult
  • New York Heart Association IV heart failure
  • Acute coronary syndrome
  • Need for acute or chronic hemodialysis
  • Acute haematological malignancies
  • Cardiogenic shock
  • Post cardiopulmonary resuscitation care
  • Immunosuppression, systemic steroid therapy (>10mg prednisolon/day)
  • Human immunodeficiency virus infection (HIV) and active AIDS
  • Patients with donated organs
  • Thrombocytopenia (<20.000/ml)
  • More than 10%-of body surface area with third degree burn

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02288975

Layout table for location information
Department of Anaesthesiology and Intensive Therapy
Szeged, Csongrád, Hungary, H-6725
Sponsors and Collaborators
Zsolt Molnár, MD, PhD, DEAA
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zsolt Molnár, MD, PhD, DEAA, Ph.D. student; Department of Anaesthesiology and Intensive Therapy, Szeged University
ClinicalTrials.gov Identifier: NCT02288975    
Other Study ID Numbers: CytoSorb-2014
First Posted: November 13, 2014    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: March 2018
Keywords provided by Zsolt Molnár, MD, PhD, DEAA, Szeged University:
extracorporeal blood purification
septic shock
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Systemic Inflammatory Response Syndrome
Pathologic Processes